Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDI Ceftin Petition Seeks ANDA Crystal, Isomer Regs

Executive Summary

FDA should develop regulations for the approval of ANDAs which differ in form, "especially crystalline form," from a listed drug, Professional Detailing, Inc. recommends in a citizen petition.

You may also be interested in...



PDI/Bayer Detailing Focuses On Cipro, Avelox After Baycol Withdrawal

PDI and Bayer are discussing which product will replace Bayer's withdrawn cholesterol-lowering agent Baycol in their contract sales agreement

PDI/Bayer Detailing Focuses On Cipro, Avelox After Baycol Withdrawal

PDI and Bayer are discussing which product will replace Bayer's withdrawn cholesterol-lowering agent Baycol in their contract sales agreement

Omeprazole Isomer Data Based On AaiPharma Patents Submitted To FDA

AaiPharma is submitting data to FDA regarding the isomer content of omeprazole (AstraZeneca's Prilosec) based on patents recently issued to the company.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel